Page 5 - டாகேடா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Japan s Takeda sells four diabetes products to Teijin Pharma for $1 25 bln

By Reuters Staff 1 Min Read Takeda Pharmaceutical Co s logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon TOKYO (Reuters) - Takeda Pharmaceutical Co said on Friday it agreed to sell four diabetes products in Japan to Teijin Pharma Ltd for 133 billion yen ($1.25 billion). Takeda will sell the Japanese marketing rights of drugs Nesina, Liovel, Inisync and Zafatek to Teijin Pharma subject to regulator approval, the company said in a release. The drugs generated 30.8 billion yen in sales in fiscal 2019, Takeda said. The sale is the latest in a series of deals that Takeda has undertaken to reduce debt and refocus its business after its purchase of Shire Ltd, which was completed in January 2019. ($1 = 106.0300 yen)

Alex richardsonTeijin pharmaThomson reuters trust principlesShire ltdTakeda pharmaceutical coJapan to teijin pharma ltdTeijin pharma ltdRocky swiftThomson reuters trustAsia pacificContent produced in bangaloreChemicals trbc level 3Company newsDivestitures spin offsHealth medicinePharmaceuticals nec trbc level 5

Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Takeda pharmaceutical company limitedAsset transferTeijin pharmaTeijin pharma limitedBusiness areasடாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவைசொத்து பரிமாற்றம்வணிக பகுதிகள்

Novavax and Takeda Finalize License Agreement for Novavax COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

Novavax and Takeda Finalize License Agreement for Novavax COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Vaccine candidateClinical trialTakeda pharmaceutical companyதடுப்பூசி வேட்பாளர்மருத்துவ சோதனைடாகேடா மருந்து நிறுவனம்

Takeda says first subject given Novavax COVID-19 vaccine in Japan clinical trial

Takeda Pharmaceutical Co said on Wednesday the first patient had been given Novavax Inc's COVID-19 vaccine candidate in a Japanese clinical trial.

Himani sarkarThomson reuters trust principlesTakeda pharmaceutical coNovavax incRocky swiftThomson reuters trustCorona virusAsia pacificCompany newsEast asiaGeneral newsHealth medicineHealthcare trbc level 1Human diseases conditionsInfectious diseasesBiotechnology amp medical research trbc level 4

Takeda Updates On Phase 1/2 Trials Of Novavax And Moderna s COVID-19 Vaccine Candidates In Japan

TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) said Wednesday that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax' COVID-19 vaccine candidate

Takeda pharmaceutical company limitedGovernment of japan ministry health labourDevices agencyJapan pharmaceuticalsPharmaceutical company limitedMedical devicesHealth labourCo vidடாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவைஅரசு ஆஃப் ஜப்பான் அமைச்சகம் ஆரோக்கியம் தொழிலாளர்ஜப்பான் மருந்துகள்மருந்து நிறுவனம் வரையறுக்கப்பட்டவைமருத்துவ சாதனங்கள்ஆரோக்கியம் தொழிலாளர்இணை வித்